216257-25-9

Basic information

• Product Name: Silane, (3,5-dichlorophenoxy)tris(1-methylethyl)-
• CAS NO: 216257-25-9
• Molecular Formula: C15H24Cl2OSi
• Molecular Weight: 319.346
• Mol File: 216257-25-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Silane, (3,5-dichlorophenoxy)tris(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, (3,5-dichlorophenoxy)tris(1-methylethyl)-(216257-25-9)
• EPA Substance Registry System: Silane, (3,5-dichlorophenoxy)tris(1-methylethyl)-(216257-25-9)

Safety Data

• Hazardous Substances Data: 216257-25-9(Hazardous Substances Data)

Upstream product

• 13154-24-0 triisopropylsilyl chloride 
• 591-35-5 3,5-dichlorophenol 
• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 

Downstream Products

• 30482-87-2 2,6-dichloro-4-methoxybenzonitrile 
• 1345732-64-0 {3-chloro-5-[(triisopropylsilyl)oxy]phenyl}(2,4-dichlorophenyl)methanone 
• 60964-09-2 2,6-dichloro-4-hydroxybenzaldehyde 
• 616195-93-8 2,6-dichloro-4-triisopropylsilyloxy-benzaldehyde 
• 1335097-16-9 4-iodo-23,5-dichloro phenol 

Relevant articles and documents

NOVEL THYROMIMETICS

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

DERIVATIVES OF SOBETIROME

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4

The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.